title: Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
abstract: The Zoladex Early Breast Cancer Research Association (ZEBRA) trial compared the efficacy and tolerability of goserelin (Zoladex) with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy in pre-/perimenopausal women with node-positive early breast cancer. The results of disease-free survival (DFS) analyses have already been published. Here we present an update including data on overall survival (OS) from the ZEBRA trial at a median follow-up of 7.3 years. In patients with oestrogen receptor (ER)-positive tumours, non-inferiority of goserelin versus CMF for OS was shown; goserelin was again shown to be equivalent to CMF for DFS. This updated analysis has demonstrated that the two treatments are also equivalent for distant disease-free survival (DDFS). In patients with ER-negative disease, goserelin was inferior to CMF for DFS, DDFS and OS. This follow-up analysis confirms the previously reported outcomes from the ZEBRA trial and demonstrates that goserelin offers an effective alternative to CMF chemotherapy for adjuvant therapy of premenopausal patients with ER-positive, node-positive early breast cancer.
authors.affiliation: Universitäts-Frauenklinik, Frankfurt, Germany. m.kaufmann@em.uni-frankfurt.de
authors.forename: M
authors.initials: M
authors.lastname: Kaufmann
authors.forename: W
authors.initials: W
authors.lastname: Jonat
authors.forename: R
authors.initials: R
authors.lastname: Blamey
authors.forename: J
authors.initials: J
authors.lastname: Cuzick
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: I
authors.initials: I
authors.lastname: Fogelman
authors.forename: J C
authors.initials: JC
authors.lastname: de Haes
authors.forename: M
authors.initials: M
authors.lastname: Schumacher
authors.forename: W
authors.initials: W
authors.lastname: Sauerbrei
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D017273:Goserelin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008207:Lymphatic Metastasis; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D017697:Premenopause; D011960:Receptors, Estrogen / Q000378:metabolism; D012307:Risk Factors; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011960:Receptors, Estrogen; D017273:Goserelin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate